Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
50.63
Oct 20 • 3:59 PM ET Dollar change+1.17 Percentage change(2.37%)
Aftermarket Close
50.52
Aftermarket • 7:50 PM ET Dollar change-0.11 Percentage change(-0.22%)
Oct 20, 8:01 PMGSK wins FDA approval for Hibsago, first-in-class antisense oligonucleotide for certain adults with chronic hepatitis B in combination with nucleos(t)ide analogue therapy
Index
-
Market Cap
101.44B
Enterprise Value
120.90B
Income
6.48B
Sales
44.55B
Book/sh
11.58
Cash/sh
2.06
Employees
66841
IPO
Mar 28, 1980
P/E
15.95
Forward P/E
10.05
PEG
2.40
P/S
2.28
P/B
4.37
P/C
24.61
P/FCF
11.63
EV/EBITDA
8.57
EV/Sales
2.71
Quick Ratio
0.52
Current Ratio
0.82
Debt/Eq
1.03
LT Debt/Eq
0.79
Option/Short
Yes / No
EPS (ttm)
3.17
EPS next Y
5.04
EPS next Q
1.33
EPS this Y
1.16%
EPS next Y
5.93%
EPS next 5Y
4.18%
EPS past 3/5Y
-25.93% 0.08%
Sales past 3/5Y
6.03% -0.31%
EPS Y/Y TTM
48.32%
Sales Y/Y TTM
8.82%
EPS Q/Q
-69.33%
Sales Q/Q
5.87%
Insider Own
0.01%
Insider Trans
0.00%
Inst Own
17.40%
Inst Trans
-2.06%
ROA
7.95%
ROE
29.69%
ROIC
15.47%
Gross Margin
73.29%
Oper. Margin
25.00%
Profit Margin
14.56%
SMA20
5.16%
SMA50
2.15%
SMA200
-3.28%
Trades
Shs Outstand
2.02B
Shs Float
2.00B
52W High
61.69 -17.94%
52W Low
42.85 18.17%
Volatility
1.95% 1.69%
ATR (14)
1.05
RSI (14)
61.79
Beta
0.30
Rel Volume
1.34
Avg Volume
4.17M
Volume
5,597,668
Perf Week
9.42%
Perf Month
-0.88%
Perf Quarter
-0.26%
Perf Half Y
-9.78%
Perf YTD
3.24%
Perf Year
14.76%
Perf 3Y
42.30%
Perf 5Y
26.04%
Perf 10Y
20.04%
Prev Close
49.46
Price
50.63
Change %
2.37%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Martinez Maria EOfficerAug 20 '26Proposed Sale52.0844,3972,312,107Aug 20 11:19 AM
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Commercial Operations and Total Research and Development. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in London, the United Kingdom.
CFO & Executive DirectorMs. Julie Belita Brown A.C.A.
M.P.H.Dr. Jesse L. Goodman M.D.
CEO & DirectorMr. Luke Victor Miels
Chief Digital & Technology OfficerMs. Shobie Ramakrishnan
Chief Scientific Officer and Head of R&DMr. Tony Wood